• TwoStep Therapeutics raised a USD 62.5 million oversubscribed Series A to advance multi-specific targeted therapies for solid tumors.
• Merck Ventures BV joined the round as a co-lead investor alongside Pfizer Ventures, with Insight Partners and Medical Excellence Capital leading.
• Proceeds will fund a first-in-human Phase 1 trial of lead peptide-drug conjugate TS-104 following FDA IND clearance.
• TwoStep’s platform uses a polyspecific integrin-binding peptide targeting five tumor-associated integrins to improve tumor coverage in heterogeneous cancers.
• The financing lifted total capital raised to USD 71.2 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck Ventures BV published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.